Trial
NCT04483687
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
Lakefront Biotherapeutics NV
Condition
Ankylosing Spondylitis
Intervention
Filgotinib
Why stopped
Development program terminated
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-11